<?xml version="1.0" encoding="UTF-8"?>
<p id="Par23">Mass spectrum (MS)-dependent strategies offer novel insights for the identification and validation of disease-related biomarkers [
 <xref ref-type="bibr" rid="CR9">9</xref>, 
 <xref ref-type="bibr" rid="CR10">10</xref>]. For example, Geyer et al
 <italic>.</italic> developed a plasma proteome analysis pipeline using label-free quantitative MS, which detected 284 ± 5 proteins containing &gt; 40 FDA-approved biomarkers without removing high-abundance proteins [
 <xref ref-type="bibr" rid="CR11">11</xref>]. Sequential windowed acquisition of all theoretical fragment ion mass spectrum (SWATH-MS) is a newly developed strategy using a data-independent acquisition (DIA) method with high quantitative accuracy and reproducibility [
 <xref ref-type="bibr" rid="CR12">12</xref>]. Using this strategy, increasing numbers of disease biomarkers have been identified, and novel criteria for disease typing based on proteomics have been established [
 <xref ref-type="bibr" rid="CR13">13</xref>–
 <xref ref-type="bibr" rid="CR15">15</xref>].
</p>
